期刊文献+

卵巢癌血清学标志物联合检测模式探讨 被引量:7

原文传递
导出
摘要 目的:探讨CA125、HE4、CA724、CEA联合检测在卵巢癌早期诊断中的价值。方法:以2011年4月~2012年4月因盆腔肿块就诊的156例疑似卵巢癌患者为研究对象,采用电化学发光法测定血清CA125、HE4、CA724、CEA值。同时选取体检中心同期进行健康体检的70位女性作为健康对照组,观察比较人群血清学肿瘤标志物表达的差异。结果:最终经病理确认,研究组中60例为卵巢癌,80例为卵巢良性疾病,16例因状态未知而未纳入后期分析。卵巢癌组的血清CA125、HE4、CA724、CEA水平显著高于卵巢良性疾病组和健康对照组(P<0.05);除外CA125,卵巢良性疾病组与对照组间其余各指标无显著性差异(P<0.05)。CA125、HE4、CA724、CEA单一指标检测卵巢癌的灵敏度分别为60%、73%、48%、20%,特异度分别为40%、90%、80%、70%。4项指标联合检测卵巢癌的灵敏度为89%,特异度为86%。结论:CA125、HE4、CA724、CEA联合检测模式是筛选特异性较高的指标,能提高检测的灵敏度,同时保持较高的特异度,是卵巢癌早期诊断的可行模式。
作者 夏俊
出处 《中国妇幼保健》 CAS 北大核心 2012年第32期5157-5158,共2页 Maternal and Child Health Care of China
  • 相关文献

参考文献12

  • 1任海花,任卫东,马惠风.卵巢癌临床流行病学调查报告[J].基层医学论坛,2009,13(2):62-63. 被引量:29
  • 2鹿红,阎晓娟.探索新的用于检测早期卵巢癌的标志物[J].中外医疗,2008,27(1):54-55. 被引量:1
  • 3王丹丹,李燕华.肿瘤标志物在卵巢癌早期诊断中的应用进展[J].实用癌症杂志,2011,26(5):522-524. 被引量:5
  • 4马列婷,王亚文,马丽娟.血清肿瘤标志物联合测定对卵巢癌的诊断价值[J].现代检验医学杂志,2009,24(2):58-60. 被引量:3
  • 5Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and im- plications for its use in clinical Screening[J].Gynecol On- col, 2003, 88 (12): 152.
  • 6Lamerz R, Thomas L. Clinical laboratory diagnosis [M ] . 1 st English Edition, Frankfurt, 1998 : 952 - 955.
  • 7Hasholzner U, Baumgartner L, Stieber Pet al. Clinical signifi- cance of the tumor markers CA 125 II and CA 72 - 4 in ovarian carcinoma [J]. Int J Cancer, 1996, 69 (4): 329.
  • 8中华人民共和国卫生部.新编常见恶性肿瘤诊治规范(第七分册)[M].北京:中国协和医科大学出版社,1999.668-673.
  • 9Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J]. Gynecol Oncol, 2008, 108 (2) : 402.
  • 10Kim YM, Whang D, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case control study in a Korean population[J]. Clin Chem Lab Med, 2011. 49 (3) . 527.

二级参考文献36

  • 1罗晓红,段朝晖,潘昆贻,王英,曾海燕.血清CA125、CA199及CEA联合检测在卵巢肿瘤诊断中的价值[J].临床和实验医学杂志,2006,5(7):878-879. 被引量:13
  • 2Robertson D M, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer [J]. Cancer Lett, 2007,249 (1) : 14-17.
  • 3Nagler R,Bahar G, Shpitzer T ,et al. Links concomitant analysis of salivary tumor markers-a new diagnostic tool for oral cancer[J]. Clin Cancer Res, 2006, 12(3) : 3979-3984.
  • 4Dede M,Gungor S,Yenen M C,et al. Links CA199 may have clinical significance in mature cystic teratomas of the ovary[J]. Int J Crynecol Cancer,2006, 16(1):189-193.
  • 5Duffy M J,Van Dalen A,Hagtund C,et al. Tumour markers in colorectal cancer ~European Group on Tumour Markers (EGTM) guidelines for clinical use [J]. Eur J Cancer,2007,43(9) : 1348-1360.
  • 6Jacobs L J,Menon U. Progress and challenges in screening for early detection of ovarian cancer[J]. Mole Cellular Proteomics, 2004,3 (4) : 355-366.
  • 7[1]Meyer T,Rustin GJ.Role of tumour markers in monitoring epithelial ovarian cancer[J].Br J Cancer.2000,82(9):1535~1538.
  • 8[2]Maggino T,Gadducci A.Serum markers as prognostic factors in epithelial ovarian cancer:an overview[J].Eur J Gynaecol Oncol.2000121(1):64-69.
  • 9[3]Bristow RE,del Carmen MG,Pannu HK,et all Clinically occult recurrent ovarian cancer:patient selection for secondary cytoreductive surgery using combined PET/ CT1[J],Gynecol Oncol.2003,90(3):5192~5281.
  • 10[4]Mok SC,Chao J,Skates S,et al.Prostasin a potential serum marker for ovarian cancer:identification through microarray technology[J].J Natl Cancer Inst.2001,93(19):1458~1564.

共引文献37

同被引文献63

引证文献7

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部